<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3514">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04678024</url>
  </required_header>
  <id_info>
    <org_study_id>COVIDIAGNOSTIX</org_study_id>
    <nct_id>NCT04678024</nct_id>
  </id_info>
  <brief_title>Sensitivity Evaluation of Serological Tests for Covid-19</brief_title>
  <acronym>COVIDIAGNOSTIX</acronym>
  <official_title>Multicentric Sensitivity Assessment of Antibody Diagnostic Tests Developed for Diagnosis of SARS-CoV2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Galeazzi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Galeazzi</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to test the diagnostic sensitivity of antibody tests&#xD;
      for the diagnosis of SARS-CoV2 infection, available to clinical laboratories, within a&#xD;
      national network of hospitals carrying out research activities. Test the diagnostic&#xD;
      specificity of antibody tests for the diagnosis of SARS-CoV2 infection. Complete a systematic&#xD;
      evaluation of the different approaches. Perform Health technology Assessment (HITA) of the&#xD;
      methodologies under study, in order to verify their reliability to the immunoglobulin levels&#xD;
      produced by each individual exposed patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 18, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>Up to 22 weeks</time_frame>
    <description>Sensitivity and Specificity Evaluation in Diagnostic Sierological tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Sensitivity and Specificity Evaluation in Diagnostic Sierological tests</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HTA</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">410</enrollment>
  <condition>Covid19</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients or individuals exposed to Sars-Cov2 Infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients or individuals exposed to Sars-Cov2 Infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        There are no criteria for excluding patients or individuals, if not the refusal to&#xD;
        participate to project&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Banfi</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Orthopedic Institute Galeazzi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Ortopedico Galeazzi</name>
      <address>
        <city>Milan</city>
        <zip>20161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>test sierologici</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

